What is a stock summary page? Click here for an overview.
Business Description
Colinz Laboratories Ltd
ISIN : INE923C01011
Compare
Compare
Traded in other countries / regions
531210.India IPO Date
1995-11-09Description
Colinz Laboratories Ltd is an India based company engaged in trading and manufacturing of pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathy, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.92 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.95 | |||||
| Interest Coverage | 10.93 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.2 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.8 | |||||
| 3-Year EBITDA Growth Rate | 41.9 | |||||
| 3-Year EPS without NRI Growth Rate | 62.5 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | 30.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.86 | |||||
| 9-Day RSI | 51.46 | |||||
| 14-Day RSI | 50.68 | |||||
| 3-1 Month Momentum % | 46.29 | |||||
| 6-1 Month Momentum % | 47.71 | |||||
| 12-1 Month Momentum % | 87.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.49 | |||||
| Quick Ratio | 3.21 | |||||
| Cash Ratio | 2.9 | |||||
| Days Inventory | 128.28 | |||||
| Days Sales Outstanding | 52.37 | |||||
| Days Payable | 96.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 18 | |||||
| Shareholder Yield % | -2.31 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.1 | |||||
| Operating Margin % | 5.87 | |||||
| Net Margin % | 7.19 | |||||
| FCF Margin % | 15.43 | |||||
| ROE % | 5.39 | |||||
| ROA % | 4.17 | |||||
| ROIC % | 6.32 | |||||
| 3-Year ROIIC % | -29.06 | |||||
| ROC (Joel Greenblatt) % | 41.69 | |||||
| ROCE % | 7.87 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.99 | |||||
| PE Ratio without NRI | 29.99 | |||||
| Shiller PE Ratio | 61.06 | |||||
| Price-to-Owner-Earnings | 11.66 | |||||
| PEG Ratio | 0.94 | |||||
| PS Ratio | 2.16 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.62 | |||||
| Price-to-Free-Cash-Flow | 13.96 | |||||
| Price-to-Operating-Cash-Flow | 13.96 | |||||
| EV-to-EBIT | 10.93 | |||||
| EV-to-EBITDA | 9.27 | |||||
| EV-to-Revenue | 1.16 | |||||
| EV-to-FCF | 6.56 | |||||
| Price-to-GF-Value | 1.24 | |||||
| Price-to-Projected-FCF | 0.87 | |||||
| Price-to-Median-PS-Value | 2.19 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.26 | |||||
| Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 2.27 | |||||
| Price-to-Net-Cash | 3.01 | |||||
| Earnings Yield (Greenblatt) % | 9.16 | |||||
| FCF Yield % | 6.84 | |||||
| Forward Rate of Return (Yacktman) % | 20 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Colinz Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 67.057 | ||
| EPS (TTM) (₹) | 1.91 | ||
| Beta | 1.67 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.79 | ||
| Volatility % | 78.22 | ||
| 14-Day RSI | 50.68 | ||
| 14-Day ATR (₹) | 3.438259 | ||
| 20-Day SMA (₹) | 62.961 | ||
| 12-1 Month Momentum % | 87.12 | ||
| 52-Week Range (₹) | 36 - 88.7 | ||
| Shares Outstanding (Mil) | 2.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Colinz Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Colinz Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Colinz Laboratories Ltd Frequently Asked Questions
What is Colinz Laboratories Ltd(BOM:531210)'s stock price today?
The current price of BOM:531210 is ₹60.01. The 52 week high of BOM:531210 is ₹88.70 and 52 week low is ₹36.00.
When is next earnings date of Colinz Laboratories Ltd(BOM:531210)?
The next earnings date of Colinz Laboratories Ltd(BOM:531210) is .
Does Colinz Laboratories Ltd(BOM:531210) pay dividends? If so, how much?
Colinz Laboratories Ltd(BOM:531210) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers